TY - JOUR
T1 - Conflict of Interest Disclosure in Oncology
T2 - Preliminary Insights From the Global ONCOTRUST-1 Cross-Sectional Study
AU - El Bairi, Khalid
AU - Najem, Salma
AU - Chowdhury, Arman Reza
AU - Omar, Abeid
AU - Abdihamid, Omar
AU - Teuwen, Laure Anne
AU - Benhima, Nada
AU - Madariaga, Ainhoa
AU - Elkefi, Safa
AU - Diaz, Fernando Cristobal
AU - Hussain, Sadaqat
AU - Jenei, Kristina
AU - Hammad, Nazik
AU - Mutebi, Miriam
AU - Rubagumya, Fidel
AU - Trapani, Dario
AU - El Kadmiri, Nadia
AU - Laouali, Nasser
AU - Fourtassi, Maryam
N1 - Publisher Copyright:
© American Society of Clinical Oncology.
PY - 2024
Y1 - 2024
N2 - PURPOSEConflicts of interest (COIs) between oncologists and industry might considerably influence how the presentation of the research results is delivered, ultimately affecting clinical decisions and policy-making. Although there are many regulations on reporting COI in high-income countries (HICs), little is known about their reporting in low-and middle-income countries (LMICs). Oncology Transparency Under Scrutiny and Tracking (ONCOTRUST-1) is a pilot global survey to explore the knowledge and perceptions of oncologists regarding COI.MATERIALS AND METHODSWe designed an online 27-question-based survey in the English language to explore the perceptions and knowledge of oncologists regarding COI, with an emphasis on LMICs. Descriptive statistics and the Consensus-Based Checklist for Reporting of Survey Studies guidelines were used to report the findings.RESULTSONCOTRUST-1 surveyed 200 oncologists, 70.9% of them practicing in LMICs. Median age of the respondents was 36 (range, 26-84) years; 47.5% of them were women. Of the respondents, 40.5% reported weekly visits by pharmaceutical representatives to their institutions. Regarding oncologists' perceptions of COI that require disclosure, direct financial benefits, such as honoraria, ranked highest (58.5%), followed by gifts from pharmaceutical representatives (50%) and travel grants for attending conferences (44.5%). By contrast, personal or institutional research funding, sample drugs, consulting or advisory board, expert testimony, and food and beverage funded by pharmaceutical industry were less frequently considered as COI. Moreover, only 24% of surveyed oncologists could correctly categorize all situations representing a COI.CONCLUSIONThese findings underscore the importance of clear guidelines, education, and transparency in reporting COI in oncology. This hypothesis-generating pilot survey provided the rationale for ONCOTRUST-2 study, which will compare perceptions of COI among oncologists in LMICs and HICs.
AB - PURPOSEConflicts of interest (COIs) between oncologists and industry might considerably influence how the presentation of the research results is delivered, ultimately affecting clinical decisions and policy-making. Although there are many regulations on reporting COI in high-income countries (HICs), little is known about their reporting in low-and middle-income countries (LMICs). Oncology Transparency Under Scrutiny and Tracking (ONCOTRUST-1) is a pilot global survey to explore the knowledge and perceptions of oncologists regarding COI.MATERIALS AND METHODSWe designed an online 27-question-based survey in the English language to explore the perceptions and knowledge of oncologists regarding COI, with an emphasis on LMICs. Descriptive statistics and the Consensus-Based Checklist for Reporting of Survey Studies guidelines were used to report the findings.RESULTSONCOTRUST-1 surveyed 200 oncologists, 70.9% of them practicing in LMICs. Median age of the respondents was 36 (range, 26-84) years; 47.5% of them were women. Of the respondents, 40.5% reported weekly visits by pharmaceutical representatives to their institutions. Regarding oncologists' perceptions of COI that require disclosure, direct financial benefits, such as honoraria, ranked highest (58.5%), followed by gifts from pharmaceutical representatives (50%) and travel grants for attending conferences (44.5%). By contrast, personal or institutional research funding, sample drugs, consulting or advisory board, expert testimony, and food and beverage funded by pharmaceutical industry were less frequently considered as COI. Moreover, only 24% of surveyed oncologists could correctly categorize all situations representing a COI.CONCLUSIONThese findings underscore the importance of clear guidelines, education, and transparency in reporting COI in oncology. This hypothesis-generating pilot survey provided the rationale for ONCOTRUST-2 study, which will compare perceptions of COI among oncologists in LMICs and HICs.
UR - https://www.scopus.com/pages/publications/85194991495
U2 - 10.1200/GO.24.00167
DO - 10.1200/GO.24.00167
M3 - Article
C2 - 38822759
AN - SCOPUS:85194991495
SN - 2378-9506
VL - 10
JO - JCO Global Oncology
JF - JCO Global Oncology
M1 - e2400167
ER -